EUCTR2006-005668-21-GB进行中（未招募）1 期
A randomised, double-blind, parallel group, multiple-dose 3 month study of ibuprofen 400mg alone, paracetamol (acetaminophen) 1000mg alone, ibuprofen 200mg plus paracetamol 500mg and ibuprofen 400mg plus paracetamol 1000mg, all taken three times daily, in community patients with chronic knee pain. - Ibuprofen plus paracetamol (acetaminophen) in knee pain.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 892
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1) Age: Age 40 years or over.
- •2) Sex: both sexes are eligible for entry. Females of child bearing potential must have a negative urine pregnancy test result at the baseline visit. (Note: this is a home visit, serum pregnancy testing is not practical).
- •3) Primary diagnosis of chronic knee pain as evidenced by the presence of pain in or around at least one knee for most days over the last three months and pain on at least four of the seven days preceding the screeing visit. Subjects taking analgesic drugs at screening must be willing to discontinue them.
- •4) Pain of the signal knee, prior to provision of study medication, and, where necessary, after an appropriate washout period on discontinuation of any current analgesic medications, at a level of >30 mm and <80 mm on the VAS (pain experienced in the previous 48 hours) for one or more of the following: walking on a flat surface, going up or down stairs, at night while in bed, sitting or lying, standing upright.
- •5) Be anticipated to require continuous treatment to control pain for the duration of the study.
- •6) Have a Functional Capacity Classification of I-III.
- •7) Status: Patients registered with a General Practitioner.
- •8) Subjects who have given written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Concomitant other major rheumatic disease (including rheumatoid arthritis, gout and sero-negative arthropathies) or other painful conditions which could interfere with the accurate assessment of the signal knee, or acute joint trauma of the signal knee or a lower limb joint prosthesis.
- •2) An anticipated need for any major surgical procedure or any invasive procedure that would be performed on either knee during the course of the study.
- •3) An active malignancy of any type (subjects who have a history of basal cell carcinoma that has been successfully treated are eligible). Subjects with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before
- •study enrolment are also eligible).
- •4) An active or suspected peptic or duodenal ulceration, a history of gastrointestinal bleeding or severe dyspepsia experienced for most days of the previous month.
- •5) Inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis), a chronic or acute renal or hepatic disorder, a significant coagulation defect, or any previous history of allergy or known intolerance to any of the drugs or formulation constituents which, in the Investigator’s opinion, might preclude use of an NSAID, including aspirin sensitive asthma or a previous allergic response to a NSAID, including bronchospasm, urticaria, angioedema and rhinitis.
- •6) Ankle oedema.
- •7) Concomitant medications and treatments (see Section 13): Receipt of any intra-articular hyaluronate in the previous 6 months, or intra-articular corticosteroids within 3 months to the signal joint or intra-articular corticosteroid to any joint within the previous 1 month, or intra-muscular (i.m.) corticosteroid or per oral (p.o.) steroid within the previous month or fluid evacuation without steroid injection, or any drug intended to modify joint structure or function; Subjects taking warfarin and other anticoagulants will be excluded, however, subjects taking = 325 mg aspirin per day for non-arthritic reasons, if stable for at least 30 days prior to first dose of study medication, are eligible. Subjects taking methotrexate will be excluded. If the patient uses a cane or other assisted devices at time of initial evaluation, then the usage must remain unchanged. If the patient is undergoing physiotherapy at the time of initial evaluation, then the regimen must remain unchanged throughout the study.
- •8) An anticipated need for treatment with other analgesics (such as opiodis/narcotics) during the course of the study.
- •9) Abnormal pre-treatment laboratory test values ?1.5 times the upper limit of normal (ULN) for either aspartate transaminase (AST; SGOT) or alanine transaminase (ALT; SGPT) or any other laboratory abnormalities considered by the Investigator to be clinically significant. If such a value is found at screening, the patient must be excluded.
- •10) Abuse of alcohol, as evidenced by averaging more than 21 units per week for men or 14 units for women.
- •11) Woman of childbearing potential, who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. an oral contraceptive, an approved hormonal implant, an intrauterine device or condoms/diaphragm and spermicide). A woman of childbearing potential is defin
研究者
相似试验
已完成
不适用
Ibuprofen plus paracetamol in knee paiISRCTN77199439RB Corporate Services Ltd (UK)800
进行中（未招募）
1 期
A study comparing cardiovascular effects of ticagrelor and clopidogrel in patients with Peripheral Artery DiseaseEUCTR2011-004616-36-HUAstraZeneca AB13,500
进行中（未招募）
1 期
A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD) - EUCLIDEUCTR2011-004616-36-BGAstraZeneca AB13,885
进行中（未招募）
1 期
A study comparing cardiovascular effects of ticagrelor and clopidogrel in patients with Peripheral Artery Diseaseperipheral artery diseaseMedDRA version: 14.1Level: LLTClassification code 10067825Term: Peripheral arterial diseaseSystem Organ Class: 100000004866EUCTR2011-004616-36-FRAstraZeneca AB11,500
进行中（未招募）
1 期
A study comparing cardiovascular effects of ticagrelor and clopidogrel in patients with Peripheral Artery DiseaseEUCTR2011-004616-36-GBAstraZeneca AB13,885